Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition
. Binding of Trast-NG to ErbB2-overexpressing breast cancer cells was confirmed by confocal microscopy. ErbB2-was visualized using a mouse monoclonal antibody directed against the C-terminal antigenic region of ErbB2 (BD Pharmingen), followed by Alexa594-conjugated anti-mouse secondary antibody. The Trast-NG bound to the ErbB2 was detected using a FITC-conjugated goat anti-human secondary antibody to detect the Fc portion of the Trast-conjugated to the NG.
In vitro cytotoxicity study.
Cytotoxicity of drug-loaded NGs was assessed in BT-474 and MCF-7 cells by a standard MTT assay (1) . Briefly, cells were seeded in 96-well plates (5,000 cells/well) and allowed to adhere for 24 h prior to the assay. Cells were exposed to various concentrations of Trast-NG/DOX and NG/DOX (0 -10 μg/mL Dox) for 48 h at 37 °C. Cells were then washed with PBS and MTT indicator dye (25 μL, 5 mg/mL) was added to each well and the cells were incubated for 2 h at 37°C in the dark. A solution of 50% DMF-20% SDS (100 μL) was added to each well and kept overnight at 37 °C. Absorbance was read at 570 nm using a plate reader (SpectraMax M5, Molecular Devices Co., USA). Cell survival rates were calculated as normalized to control untreated wells. All measurements were taken eight times. Based on the results of the test, the IC 50 values were calculated by using GraphPad Prism 5 (GraphPad Software, Inc.). The lysosomal marker LAMP-1 (seen in red) was stained using mouse anti-human LAMP-1 mAb, followed by Alexa-594-conjugated anti-mouse secondary. Co-localization of Trast-NG with LAMP-1 can be seen as regions in yellow/orange. 
In vivo antitumor efficacy of Trast-NG/DOX in

ErbB2 degradation in tumor sections
Figure S7. ErbB2 levels analyzed in the tumor sections using A) western blot and B) ErbB2-IHCs. 
